Cholera conjugate vaccine

A cholera conjugate vaccine (CCV) is a parenteral (injectable) vaccine designed to protect against infection by *Vibrio cholerae*, the bacterium that causes cholera. The key innovation of this vaccine is the chemical linkage (conjugation) of the O-specific polysaccharide (OSP) from *V. cholerae* O1 to a protein carrier, such as a recombinant fragment of tetanus toxoid. This conjugation enhances immunogenicity, especially in young children, by inducing robust T cell-dependent immune responses and strong IgG antibody production against the bacterial polysaccharide antigen[3][5][8]. Unlike oral killed or live vaccines, which are less effective in children under five years old and not licensed for infants, CCVs are being developed specifically to improve efficacy and duration of protection in these vulnerable populations[6][8]. The mechanism of action involves generating high levels of anti-OSP IgG antibodies that can appear in mucosal fluids and provide both systemic and mucosal immunity[8]. Development efforts have been led by Massachusetts General Hospital/Harvard University researchers with support from IVI (International Vaccine Institute), EuBiologics, Biovac Institute, Incepta Vaccine Ltd., BIBCOL, Biological E Ltd., Wellcome Trust, RIGHT Foundation, Open Philanthropy, NIH funding among others[6].

Other names

CCV